Investors / United Kingdom / Advent Life Sciences
Advent Life Sciences
Venture capital · London, United Kingdom · Europe
Advent Life Sciences is a trans-Atlantic venture capital firm that builds life sciences businesses. It starts and invests in early and mid-stage companies, working hands-on with management teams to turn science into approved medicines or medical products.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechmedtechdrug discoveryvaccinestherapeutics
Your fit with Advent Life Sciences
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsAdvent Life Sciences lists 39 checked portfolio companies on its own site and is named in 4 funding rounds, 1 of them as lead. Its most frequent entry is Series B, 50% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 38% of its companies are based in United States. It invests most often alongside Columbus Venture Partners, Cambridge Innovation Capital and F-Prime Capital.
Counts come from funding rounds that name Advent Life Sciences, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Advent Life Sciences' whole history. Rounds on record name 4 companies; its own site lists 39. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 0% |
| Series B | 50% |
| Growth | 50% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 2 | 0 |
| '26 | 2 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 77th | 39 companies |
| Recent activity | 69th | 2 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 72th | 8% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 95th | 10 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Columbus Venture Partners | 5 |
| Cambridge Innovation Capital | 3 |
| F-Prime Capital | 3 |
| Foresite Capital | 3 |
| NEA | 3 |
| Aisling Capital | 2 |
| BGF | 2 |
| British Business Bank | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers3795%
- No longer answers00%
- Points to another company25%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Columbus Venture Partners
Compare Advent Life Sciences head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Funds
from public registers and its siteRecent portfolio activity
when companies last raised with Advent Life Sciences| Date | Company | Stage |
|---|---|---|
| 5 Nov 2026 | Series B Led | |
| 8 Jan 2026 | Series C+ | |
| 2 Sept 2025 | Series B | |
| 16 Apr 2025 | Series C+ |
Round details for Advent Life Sciences
Amounts, full round histories and every co-investor in Advent Life Sciences' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
39 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Agenus develops immunotherapies to defeat cancer | Healthcare & Biotech | Portfolio page | ||
| Aleta Biotherapeutics develops biologic therapies to enhance the effectiveness of CAR T cell therapies in treating cancer. | Healthcare & Biotech | Portfolio page | ||
| AlphaRose Therapeutics engineers and commercializes medicines for patients with genetic diseases | Healthcare & Biotech | Portfolio page | ||
| Amphista Therapeutics is developing drugs to bring life-changing medicines to patients | Healthcare & Biotech | Portfolio page | ||
| Argá Medtech develops technology for cardiac ablation to treat atrial fibrillation | Healthcare & Biotech | Portfolio page | ||
| Arrakis Therapeutics creates genetic medicines, specifically RNA-targeted small molecules, to treat various diseases. | Healthcare & Biotech | Portfolio page | ||
| Artax Biopharma develops treatments for autoimmune diseases | Healthcare & Biotech | Portfolio page | ||
| Aura Biosciences is a clinical-stage biotechnology company that develops targeted oncology therapies for ocular cancers. | Healthcare & Biotech | Portfolio page | ||
| AviadoBio develops gene therapies for neurodegenerative diseases | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Beacon Therapeutics is a biotechnology company that develops gene therapies for ocular diseases | Healthcare & Biotech | Jan 2026Series C+ | Page + round | |
| Biocartis develops and provides molecular testing systems for oncology and other applications | Healthcare & Biotech | Portfolio page | ||
| Centessa Pharmaceuticals develops and pursues medicines for patients with various disorders, including sleep-wake, neurological, neurodegenerative and neuropsychiatric disorders. | Healthcare & Biotech | Portfolio page | ||
| The company develops innovative cyclic peptide and small molecule drugs to treat diseases such as cancer, immunology and inflammation. | Healthcare & Biotech | Portfolio page | ||
| Cyted Health develops a diagnostic platform for early detection of esophageal disease | Healthcare & Biotech | Sept 2025Series B | Page + round | |
| Eloxx Pharmaceuticals develops a small molecule called exaluren to treat rare kidney diseases caused by nonsense mutations. | Healthcare & Biotech | Portfolio page | ||
| Emergent BioSolutions develops, manufactures, and supplies medical countermeasures and commercial products for public health threats | Healthcare & Biotech | Portfolio page | ||
| Epitopea develops cancer RNA immunotherapies | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| F2G develops therapeutics for rare fungal infections | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- adventls.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 16 Apr 2025
- Companies checked
- 39
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Advent Life Sciences' profile as data
Pull Advent Life Sciences' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/adventls.com
# also
GET /v1/firms/adventls.com/portfolio
GET /v1/firms/adventls.com/coinvestors
GET /v1/firms/adventls.com/news